{"entity":{"id":"elena-elez","kind":"person","name":"Elena Élez","aka":[],"tldr":"Elena Élez is a colorectal cancer investigator who led the BREAKWATER trial's clinical programme.","summary":"Elena Élez is Head of the Gastrointestinal and Endocrine Tumours Group at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona. Her specialisms are colorectal cancer, BRAF- and KRAS-mutant disease and precision oncology. She was a principal investigator of BREAKWATER, the trial of encorafenib in BRAF-mutant colorectal cancer, and of trials of KRAS G12C inhibitors in colorectal cancer. Her papers include the updated results and subgroup analyses of the BEACON study establishing encorafenib plus cetuximab in previously treated BRAF V600E-mutant metastatic colorectal cancer, a review of prognosis and treatment in BRAF mutant colorectal cancer, and a phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib. Her publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elez%20E%5BAuthor%5D%20colorectal%20BRAF"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["braf","kras"],"drugs":["encorafenib"],"companies":[],"institutions":["vall-dhebron"],"pathways":[],"terms":[],"trials":["breakwater"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head, Gastrointestinal and Endocrine Tumours Group, VHIO","institutionId":"vall-dhebron","specialisms":["Colorectal cancer","BRAF and KRAS-mutant disease","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Elez%20E%5BAuthor%5D%20colorectal%20BRAF"}],"papers":[{"title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","journal":"Journal of Clinical Oncology","year":2021,"doi":"10.1200/jco.20.02088"},{"title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","journal":"Annals of Oncology","year":2017,"doi":"10.1093/annonc/mdx401"},{"title":"A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer","journal":"Cancer Discovery","year":2017,"doi":"10.1158/2159-8290.cd-16-0795"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","journal":"New England Journal of Medicine","year":2020,"url":"https://doi.org/10.1056/NEJMoa2017699","doi":"10.1056/NEJMoa2017699"}]},"route":"/people/elena-elez/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"braf","kind":"target","name":"BRAF","route":"/targets/braf/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"drug":[{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"institution":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"trial":[{"id":"beacon-crc","kind":"trial","name":"BEACON CRC","route":"/trials/beacon-crc/"},{"id":"breakwater","kind":"trial","name":"BREAKWATER","route":"/trials/breakwater/"}],"paper":[{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/"},{"id":"paper-keynote-177-nejm-2020","kind":"paper","name":"KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer","route":"/key-papers/paper-keynote-177-nejm-2020/"}]}}